Galectin Therapeutics (NASDAQ:GALT) Coverage Initiated by Analysts at began coverage on shares of Galectin Therapeutics (NASDAQ:GALTGet Rating) in a research report issued on Sunday. The firm set a “sell” rating on the stock.

A number of other analysts have also recently weighed in on GALT. Zacks Investment Research upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 19th. HC Wainwright reissued a “buy” rating on shares of Galectin Therapeutics in a research report on Friday, April 1st.

Shares of GALT opened at $1.55 on Friday. Galectin Therapeutics has a twelve month low of $1.46 and a twelve month high of $4.57. The company has a market cap of $91.98 million, a P/E ratio of -2.98 and a beta of 1.72. The company has a current ratio of 4.63, a quick ratio of 4.63 and a debt-to-equity ratio of 79.37. The company’s fifty day simple moving average is $1.72 and its 200-day simple moving average is $2.21.

Galectin Therapeutics (NASDAQ:GALTGet Rating) last posted its quarterly earnings results on Thursday, March 31st. The company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.07. Analysts predict that Galectin Therapeutics will post -0.42 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in GALT. Virtu Financial LLC acquired a new position in shares of Galectin Therapeutics during the fourth quarter worth about $37,000. Buckingham Strategic Wealth LLC acquired a new stake in Galectin Therapeutics during the 3rd quarter worth $42,000. Commonwealth Equity Services LLC acquired a new stake in Galectin Therapeutics during the 3rd quarter worth $46,000. Raymond James & Associates acquired a new stake in Galectin Therapeutics during the 3rd quarter worth $51,000. Finally, Benjamin F. Edwards & Company Inc. raised its position in Galectin Therapeutics by 25.5% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 29,615 shares of the company’s stock worth $61,000 after buying an additional 6,015 shares during the last quarter. Institutional investors own 12.25% of the company’s stock.

Galectin Therapeutics Company Profile (Get Rating)

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

See Also

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with's FREE daily email newsletter.